SignalXSignalX

PCVX Vaxcyte, Inc.

Q3 2025 10-Q
Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR
Vaxcyte, Inc. Overview

Vaxcyte, Inc. (PCVX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New risk: Delays in drug substance manufacturing campaign due to Lonza capacity constraints impacting VAX-24 IND timelines
  • • Updated financial risk: Net losses $212.8M Q3 2025 vs $103.1M Q3 2024; accumulated deficit $1.9B as of September 30, 2025
+3 more insights

Quarterly Financial Summary
XBRL

Net Income

-$213M

ROE

-7.4%

Total Assets

$3.2B

Source: XBRL data from Vaxcyte, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Vaxcyte, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.